The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?

Molecular and Cellular Neuroscience

Volumn 42, Issue 4, 2009, Pages 438-447

  Logue, Sheree F ^a   Grauer, Steven M ^a   Paulsen, Janet ^b   Graf, Radka ^a   Taylor, Noel ^b   Sung, M Amy ^a   Zhang, Lynn ^b   Hughes, Zoë ^a   Pulito, Virginia L ^a   Liu, Feng ^a   Rosenzweig Lipson, Sharon ^a   Brandon, Nicholas J ^a   Marquis, Karen L ^a   Bates, Brian ^b   Pausch, Mark ^a  

^a PFIZER INC   (United States)

^b Discovery Biological Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; APOMORPHINE; DOPAMINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 88; HALOPERIDOL; PHOSPHOPROTEIN DARPP 32; RISPERIDONE; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PHOSPHORYLATION; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR DENSITY; SCHIZOPHRENIA; STARTLE REFLEX; STEREOTYPY; WILD TYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; BRAIN; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HUMANS; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED; RISPERIDONE; STARTLE REACTION;

MUS; RODENTIA;

EID: 70449529748     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2009.09.007     Document Type: Article

References (50)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 7 Suppl. 1 (2004) S1-S5
2. Abi-Dargham A., and Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry: J. Assoc. Eur. Psychiatrists 20 (2005) 15-27
3. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
4. Befort K., Filliol D., Ghate A., Darcq E., Matifas A., Muller J., Lardenois A., Thibault C., Dembele D., Le Merrer J., Becker J.A.J., Poch O., and Kieffer B.L. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Eur. J. Neurosci. 27 (2008) 2973-2984
5. Bonci A., and Hopf F.W. The dopamine D2 receptor: new surprises from an old friend. Neuron 47 (2005) 335-338
6. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156 (2001) 234-258
7. Brandish P.E., Su M., Holder D.J., Hodor P., Szumiloski J., Kleinhanz R.R., Forbes J.E., McWhorter M.E., Duenwald S.J., Parrish M.L., Na S., Liu Y., Phillips R.L., Renger J.J., Sankaranarayanan S., Simon A.J., and Scolnick E.M. Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron 45 (2005) 861-872
8. Cadenhead K.S., Light G.A., Geyer M.A., and Braff D.L. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am. J. Psychiatry 157 (2000) 55-59
9. Cadenhead K.S., Swerdlow N.R., Shafer K.M., Diaz M., and Braff D.L. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am. J. Psychiatry 157 (2000) 1660-1668
10. Carpenter Jr. W.T., and Buchanan R.W. Schizophrenia. N. Engl. J. Med. 330 (1994) 681-690
11. Conti B., Maier R., Barr A.M., Morale M.C., Lu X., Sanna P.P., Bilbe G., Hoyer D., and Bartfai T. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol. Psychiatry 12 (2007) 167-189
12. Costall B., Naylor R.J., and Neumeyer J.L. Differences in the nature of the stereotyped behaviour induced by apomorphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur. J. Pharmacol. 31 (1975) 1-16
13. Costall B., Naylor R.J., and Nohria V. On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behaviour in the mouse [proceedings]. Br. J. Pharmacol 68 (1980) 175P-176P
14. Culm K.E., Lim A.M., Onton J.A., and Hammer R.P. Reduced Gi and Go protein function in the rat nucleus accumbens attenuates sensorimotor gating deficits. Brain Res 982 (2003) 12-18
15. Curran C., Byrappa N., and McBride A. Stimulant psychosis: systematic review. Br. J. Psychiatry 185 (2004) 196-204
16. Dirks A., Groenink L., Westphal K.G.C., Olivier J.D.A., Verdouw P.M., van der Gugten J., Geyer M.A., and Olivier B. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 1790-1798
17. Duncan G.E., Moy S.S., Lieberman J.A., and Koller B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology (Berl) 184 (2006) 190-200
18. Fienberg A.A., and Greengard P. The DARPP-32 knockout mouse. Brain Res. Brain Res. Rev. 31 (2000) 313-319
19. Geyer M.A., and Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1071-1079
20. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
21. Ghate A., Befort K., Becker J.A.J., Filliol D., Bole-Feysot C., Demebele D., Jost B., Koch M., and Kieffer B.L. Identification of novel striatal genes by expression profiling in adult mouse brain. Neuroscience 146 (2007) 1182-1192
22. Guo W., Shi L., Filizola M., Weinstein H., and Javitch J.A. From the cover: crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17495-17500
23. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
24. Horvitz J.C. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 96 (2000) 651-656
25. Kaiser R., Tremblay P.B., Klufmoller F., Roots I., and Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol. Psychiatry 7 (2002) 695-705
26. Kinkead B., Dobner P.R., Egnatashvili V., Murray T., Deitemeyer N., and Nemeroff C.B. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther. 315 (2005) 256-264
27. Le-Niculescu H., Balaraman Y., Patel S., Tan J., Sidhu K., Jerome R.E., Edenberg H.J., Kuczenski R., Geyer M.A., Nurnberger J.I., Faraone S.V., Tsuang M.T., and Niculescu A.B. Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 129-158
28. Le-Niculescu H., McFarland M.J., Mamidipalli S., Ogden C.A., Kuczenski R., Kurian S.M., Salomon D.R., Tsuang M.T., Nurnberger J.I., and Niculescu A.B. Convergent functional genomics of bipolar disorder: from animal model pharmacogenomics to human genetics and biomarkers. Neurosci. Biobehav. Rev. 31 (2007) 897-903
29. Lindvall O., and Bjorklund A. Dopamine- and norepinephrine-containing neuron systems: their anatomy in the rat brain. In: Emson P. (Ed). Chemical Neruoanatomy (1983), Raven Press, New York 229-255
30. Marquis K.L., Sabb A.L., Logue S.F., Brennan J.A., Piesla M.J., Comery T.A., Grauer S.M., Ashby Jr. C.R., Nguyen H.Q., Dawson L.A., Barrett J.E., Stack G., Meltzer H.Y., Harrison B.L., and Rosenzweig-Lipson S. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepin o[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J. Pharmacol. Exp. Ther 320 (2007) 486-496 10.1124/jpet.106.106989
31. Masand P.S. Weight gain associated with psychotropic drugs. Expert Opin. Pharmacother. 1 (2000) 377-389
32. Matsui-Sakata A., Ohtani H., and Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab. Pharmacokineti. 20 (2005) 187-199
33. McCaughran Jr. J., Mahjubi E., Decena E., and Hitzemann R. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (Berl) 134 (1997) 131-139
34. Mizushima K., Miyamoto Y., Tsukahara F., Hirai M., Sakaki Y., and Ito T. A novel G-protein-coupled receptor gene expressed in striatum. Genomics 69 (2000) 314-321
35. Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog. Neurobiol. 14 (1980) 69-97
36. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., and Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 72 (2004) 29-39
37. O'Donnell P. Mesolimbic-mesocortical loops may encode saliency, not just reward. Behav. Brain Sci. 28 (2005) 360-361
38. Ogden C.A., Rich M.E., Schork N.J., Paulus M.P., Geyer M.A., Lohr J.B., Kuczenski R., and Niculescu A.B. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach [Review]. Mol. Psychiatry 9 (2004) 1007-1029
39. Ouimet C.C., and Greengard P. Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J. Neurocytol. 19 (1990) 39-52
40. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd ed. (1986), Academic Press, Sydney
41. Ralph R.J., Varty G.B., Kelly M.A., Wang Y.-M., Caron M.G., Rubinstein M., Grandy D.K., Low M.J., and Geyer M.A. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J. Neurosci. 19 (1999) 4627-4633
42. Seeman P., Chau-Wong M., Tedesco J., and Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. U. S. A. 72 (1975) 4376-4380
43. Seeman P., Weinshenker D., Quirion R., Srivastava L.K., Bhardwaj S.K., Grandy D.K., Premont R.T., Sotnikova T.D., Boksa P., El-Ghundi M., O'Dowd B.F., George S.R., Perreault M.L., Mannisto P.T., Robinson S., Palmiter R.D., and Tallerico T. Dopamine supersensitivity correlates with D2 high states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3513-3518
44. Svenningsson P., Nairn A.C., and Greengard P. DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J. 7 (2005) E353-E360
45. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., and Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415 10.1126/science.1089681
46. Swerdlow N.R., Braff D.L., and Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav. Pharmacol. 11 (2000) 185-204
47. Tauscher J., Kufferle B., Asenbaum S., Tauscher-Wisniewski S., and Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 162 (2002) 42-49
48. Wynn J.K., Dawson M.E., Schell A.M., McGee M., Salveson D., and Green M.F. Prepulse facilitation and prepulse inhibition in schizophrenia patients and their unaffected siblings. Biol. Psychiatry 55 (2004) 518-523
49. Xiao X.Q., Grove K.L., Lau S.Y., McWeeney S., and Smith M.S. Deoxyribonucleic acid microarray analysis of gene expression pattern in the arcuate nucleus/ventromedial nucleus of hypothalamus during lactation. Endocrinology 146 (2005) 4391-4398
50. Yamada Y., Ohno Y., Nakashima Y., Fukuda M., Takayanagi R., Sato H., Tsuchiya F., Sawada Y., and Iga T. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse 46 (2002) 32-37